Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-06: Form 8-K; Period of report 2018-12-05; Description 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.02.
- 2018-12-06: Form 8-K; Period of report 2018-12-05; Description 8.01 Other Events; Details 8.01.
- 2018-11-01: Form 8-K; Period of report 2018-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-09-13: Form 8-K; Period of report 2018-09-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-06 | 8-K | 2018-12-05 | 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.02 On December 5, 2018, Conatus Pharmaceuticals Inc. (the “Company”), at its option, converted the entire outstanding principal of $15.0 million and accrued and unpaid interest of the convertible promissory note (the “Note”) it issued to Novartis Pharma AG (“Novartis”) in February 2017 into 2,882,519 shares of the Company’s common stock. 3.02 The information set forth in Item 1.02 above is incorporated by reference into this Item 3.02. | f8k_120618.htm |
| 2018-12-06 | 8-K | 2018-12-05 | 8.01 Other Events | 8.01 On December 5, 2018, Conatus Pharmaceuticals Inc. (the “Company”) announced top-line results from the Company’s Phase 2b ENCORE-PH clinical trial of emricasan, the Company’s first-in-class, orally active pan-caspase inhibitor under development in compensated or early decompensated nonalcoholic steatohepatitis (“NASH”) cirrhosis patients with severe portal hypertension. | f8k_120618.htm |
| 2018-11-01 | 8-K | 2018-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2018, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2018. | f8k_110118.htm |
| 2018-09-13 | 8-K | 2018-09-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 12, 2018, James Scopa resigned from the Board of Directors (the “Board”) of Conatus Pharmaceuticals Inc. (the “Company”). | f8k_091318.htm |
| 2018-08-01 | 8-K | 2018-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2018, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and six months ended June 30, 2018. | f8k_080118.htm |
| 2018-06-25 | 8-K | 2018-06-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2018. | f8k_062518.htm |
| 2018-05-02 | 8-K | 2018-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2018, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2018. | f8k_050218.htm |
| 2018-04-04 | 8-K | 2018-04-04 | 8.01 Other Events | 8.01 On April 4, 2018, Conatus Pharmaceuticals Inc. (the “Company”) announced top-line results from the Company’s exploratory Phase 2b POLT-HCV-SVR proof-of-concept clinical trial of emricasan, he Company’s first-in-class, orally active pan-caspase inhibitor, in liver transplant patients with fibrosis or cirrhosis. | f8k_040418.htm |
| 2018-03-07 | 8-K | 2018-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2018, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2017. | f8k_030718.htm |
| 2018-02-05 | 8-K | 2018-01-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 30, 2018, the Compensation Committee of the Board of Directors of Conatus Pharmaceuticals Inc. established the base salaries to be paid to the executive officers listed below, effective January 1, 2018, set target cash bonuses for the 2018 fiscal year for each of the executive officers listed below and approved cash bonus payments for the 2017 fiscal year to be paid to each of the executive officers listed below. | f8k_020518.htm |